Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors

scientific article published on 01 September 1995

Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/01.ATV.15.9.1263
P953full work available at URLhttps://www.ahajournals.org/doi/full/10.1161/01.ATV.15.9.1263
P698PubMed publication ID7670937

P2093author name stringA. Simon
J. Levenson
P. Giral
J. Gariepy
M. Razavian
P2860cites workThe pathogenesis of atherosclerosis: a perspective for the 1990sQ29547827
The New England Journal of MedicineQ582728
Increase in erythrocyte disaggregation shear stress in hypertensionQ33230945
Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health StudyQ33612628
Fibrinogen: a possible link between social class and coronary heart diseaseQ34488611
Atherosclerosis and the coagulation systemQ38713518
Role of endothelium in sequestration of lipoprotein and firbrinogen in aortic lesions, thrombi, and graft pseudo-intimasQ39568898
Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosisQ40279327
Insoluble "fibrin" in human aortic intima. Quantitative studies on the relationship between insoluble "fibrin", soluble fibrinogen and low density lipoproteinQ40302035
Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literatureQ40904739
Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrationsQ41887737
Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studiesQ43950275
Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.Q44082955
Genetic and cultural inheritance of plasma fibrinogen concentrationQ47391741
Fibrinogen and risk of cardiovascular disease. The Framingham Study.Q52588834
Relation between extent of coronary artery disease and blood viscosity.Q54965703
Fibrinogen, factor VII clotting activity and coronary artery disease severityQ67255139
Hypercholesterolaemia alters arterial and blood factors related to atherosclerosis in hypertensionQ67569162
Fate of fibrinogen in human arterial intimaQ68735946
Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosisQ69662969
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart StudyQ69886150
Risk factors in middle age that predict early and late onset of coronary heart diseaseQ69949126
Risk factors and early extracoronary atherosclerotic plaques detected by three-site ultrasound imaging in hypercholesterolemic men. Prévention Cardio-vasculaire en Médecine du Travail METRA GroupQ70145901
Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentrationQ70782550
Haemostatic function and cardiovascular death: early results of a prospective studyQ72423400
Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic diseaseQ72639026
Longitudinal associations between plasma viscosity and cardiovascular risk factors in a middle-aged French populationQ72672917
P433issue9
P407language of work or nameEnglishQ1860
P304page(s)1263-1268
P577publication date1995-09-01
P1433published inArteriosclerosis, Thrombosis, and Vascular BiologyQ4797542
P1476titleFibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors
Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors
P478volume15

Reverse relations

cites work (P2860)
Q43787052A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study
Q42837232Association between laboratory markers and presence of coronary artery disease
Q43919582Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).
Q74137858Association of plasma viscosity and carotid thickening in a French working cohort
Q38439938Association of serum immunoglobulin-G to Porphyromonas gingivalis with acute cerebral infarction in the Chinese population
Q33729553Clinical correlation between N-terminal pro-B-type natriuretic peptide and angiographic coronary atherosclerosis
Q33911689Control of fibrinogen biosynthesis: role of the FFA/albumin ratio
Q36708368Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT)
Q35802635Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia
Q24793954Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes
Q54129425Erythrocyte antioxidant status in asymptomatic hypercholesterolemic men.
Q34100016Erythrocyte, but not plasma, vitamin E concentration is associated with carotid intima-media thickening in asymptomatic men at risk for cardiovascular disease
Q33738532Expanded network of inflammatory markers of atherogenesis: where are we now?
Q73637155Fibrinogen is an efficient antioxidant
Q50907848Fibrinogen is an independent marker for thoracic aortic atherosclerosis.
Q35538771Fibrinogen: biochemistry, epidemiology and determinants
Q75319402Impaired fibrinolytic activity is present in children with dyslipidemias
Q37149080Iron-induced fibrin in cardiovascular disease
Q43850656Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.
Q34310277Pathophysiology of oxidative stress in diabetes mellitus
Q41560071Pharmacological approaches and strategies for therapeutic modulation of fibrinogen
Q73022835Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude
Q35610165Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1.
Q28369047Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
Q35024896Stress and the inflammatory response: a review of neurogenic inflammation
Q34500682Stress, inflammation and cardiovascular disease
Q73644431Study of vitamin E net mass transfer between alpha-tocopherol-enriched HDL and erythrocytes: application to asymptomatic hypercholesterolemic men
Q43419630Systemic lupus erythematosus and cardiovascular disease
Q56891683Vasoactive effects of fibrinogen on saphenous vein
Q37022169What's going on in LDL apheresis